NCT03169335View on ClinicalTrials.gov

Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

535

Participants

Timeline

Start Date

March 28, 2017

Primary Completion Date

June 23, 2018

Study Completion Date

July 13, 2018

Conditions

Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG

QL1101

targeted vascular endothelial growth factor (VEGF) monoclonal antibodies

DRUG

Avastin®

targeted vascular endothelial growth factor (VEGF) monoclonal antibodies

DRUG

Paclitaxel

175 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.

DRUG

Carboplatin

AUC 5 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.

Trial Locations (2)

Unknown

Shanghai Chest hospital, Shanghai

Tianjin Chest hospital, Tianjin

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT03169335 - Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter